Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/12/2844737/0/en/Intrommune-Therapeutics-Strengthens-Board-of-Directors-with-Appointments-of-Dr-Jonathan-Rich-and-Hem-Pandya.html
https://www.globenewswire.com//news-release/2024/02/22/2833802/0/en/Intrommune-Therapeutics-Presents-Supporting-Data-Introducing-a-New-Form-of-Food-Allergy-Treatment.html
https://www.globenewswire.com//news-release/2024/02/06/2824466/0/en/Intrommune-Therapeutics-To-Present-A-New-Form-Of-Allergy-Treatment-At-The-2024-American-Academy-Of-Allergy-Asthma-Immunology-AAAAI-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/01/08/2805548/0/en/Inimmune-Corporation-and-Intrommune-Therapeutics-announce-a-collaboration-to-advance-a-revolutionary-rapid-long-acting-oral-mucosal-allergy-immunotherapy-for-the-treatment-of-peanu.html
https://www.globenewswire.com//news-release/2023/11/09/2777585/0/en/Intrommune-Therapeutics-Presents-Positive-Results-of-Phase-1-OMEGA-Study-Investigating-the-Safety-of-INT301-Toothpaste-for-the-Treatment-of-Peanut-Allergy.html
https://www.globenewswire.com/news-release/2023/07/25/2710563/0/en/Intrommune-Therapeutics-Completes-Last-Patient-Last-Visit-in-the-Phase-1-OMEGA-Study-for-Peanut-Allergy.html
https://www.globenewswire.com/news-release/2022/10/26/2541990/0/en/Intrommune-Therapeutics-Completes-Enrollment-in-the-Phase-1-OMEGA-Study-for-Peanut-Allergy.html
https://www.globenewswire.com/news-release/2022/09/28/2524437/0/en/Intrommune-Expands-and-Strengthens-Senior-Leadership-Team.html
https://www.globenewswire.com/news-release/2022/06/22/2467244/0/en/Intrommune-Announces-Expanded-Scope-of-Phase-1-OMEGA-Study-in-Adults-with-Peanut-Allergy.html
https://www.globenewswire.com/news-release/2022/06/01/2454642/0/en/Intrommune-Therapeutics-Names-Nandini-Murthy-as-Head-of-Regulatory.html